ClinicalTrials.gg
CompletedNCT06153329Updated Dec 1, 2023

A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese Subjects

A Phase 1 interventional study of THDB0206 injection and Humalog® in Healthy, sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Jun 2021, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This is a single-center, single-dose, open-label, positive-controlled, randomized, three-cycle, crossover 8-hour euglycemic clamp study to evaluate the PK, PD, safety and tolerability of THDB0206 injection after subcutaneous injection in healthy Chinese subjects. This trial will enroll 39 subjects to receive the investigational medicinal products.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tonghua Dongbao Pharmaceutical Co.,Ltd is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who provide a signed and dated form (Appendix 1) before starting any study-related activities (study-related activities are any procedures that will not be involved during the normal management of subjects).
  2. Healthy local Chinese males or females, who complete medical history, physical examination and laboratory tests according to the judgment of the investigator.
  3. Aged ≥ 18 years and ≤ 40 years when signing the informed consent form.
  4. (BMI) ≥ 18 kg/m2 and \< 25 kg/m2 at screening, male weight ≥ 50 kg, female weight ≥ 45 kg.
  5. Intravenous fasting blood glucose \< 6.1 mmol/L and intravenous blood glucose \< 7.8 mmol/L 2 hours after the glucose load in the 75 g oral glucose tolerance test at screening.
  6. According to local laboratory analysis, HbA1c≤6.1% st screening.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

  1. Known or suspected allergies to medicinal products and related products, or a history of multiple and/or severe allergies to drugs or food.
  2. Subjects who have previously participated in this study (participation in the study is defined as randomization), or received any drugs in the clinical development stage within 3 months before the screening of this study.
  3. Any cancer or history of cancer, including basal cell skin cancer or squamous cell skin cancer.
  4. According to the judgment of the investigator, any cardiovascular, respiratory, gastrointestinal, liver, kidney, metabolism, endocrine, hematology (bleeding diseases), skin, venereal disease, nervous system, mental disease or other major diseases or related medical history.
  5. During the screening visit, abnormal values of hematology, blood biochemistry, blood coagulation or urinalysis have clinical significance, and the investigator judges and considers potential diseases.
  6. According to the judgment of the investigator, the results of the insulin release test has clinically significant abnormalities at screening.
  7. Heart problems, defined as the presence of decompensated heart failure ( Class III and IV) at any time and/or angina pectoris within 12 months prior to screening and/or acute myocardial infarction at any time.
  8. According to the judgment of the investigator, the blood pressure has clinically significant abnormalities at screening.
  9. The heart rate detected by 12-lead at rest exceeds the range of 50-100 beats per minute (including 50 and 100 beats).
  10. According to the judgment of the investigator, the standard 12-lead ECG has clinically significant abnormalities at screening.
  11. Increased risk of thromboembolism, such as known coagulopathy, (family) history of thrombosis, related arrhythmias (e.g., paroxysmal atrial fibrillation), etc.
  12. Mental disorders or language barriers which prevent full understanding or cooperation.
  13. According to the investigator's judgment, there is a history of deep vein thrombosis in the lower extremities or a first-degree relative (parents, siblings or children) frequently develops deep vein thrombosis in the lower extremities.
  14. Any disease or condition that the investigator believes will pose an unacceptable risk to the safety of the subjects.
  15. Subjects who have used any drugs (prescription drugs and over-the-counter drugs) within 14 days before administration of the IMP or within 5 times the elimination half-life of the IMP (whichever is longer).
  16. According to the investigator's judgment, subjects with a history of alcoholism or drug/chemical drug abuse, or subjects with positive drug screening/breath alcohol test results during the screening visit, or subjects drinking more than 21 units of alcohol per week (male subjects) or 14 units of alcohol (female subjects) (1 unit of alcohol is equivalent to approximately 330 mL of beer, 1 glass of 120 mL of wine or 40 mL of spirits).
  17. Subjects who have smoked more than 5 cigarettes per day on average within one year before the screening visit and do not agree to quit smoking during the study period.
  18. Female subjects who have a positive pregnancy test result during the screening visit or on Day -1 of Visit 2.
  19. According to the diagnostic test used locally, surface antigen or antibody is positive (or active hepatitis is diagnosed according to local practice), or (HIV) antibody test result is positive, or syphilis test result is positive.
  20. Subjects who have donated blood or plasma in the past month, or donated more than 300 mL within 3 months before the screening visit.
  21. During the period from the first administration to the end of the study, male subjects who are sexually active and have not been sterilized, and their female partners who are still fertile, the subjects themselves and their partners not using effective measures (effective contraceptive measures mean methods that have an unintended pregnancy rate of less than 1% each year, including surgical sterilization, condoms, intrauterine device (birth control ring), abstinence).
  22. Women of childbearing age who are pregnant, breastfeeding, preparing for pregnancy, and have not used effective contraceptive measures, or women who have had less than 1 year of amenorrhea and serum follicle stimulating hormone (FSH) level ≤ 40 IU/L and have not used effective contraceptive measures.
  23. During the COVID-19 pandemic period, those who have lived or traveled in areas with a high incidence of COVID-19, have contact history with confirmed or suspected infected people, have a history of fever clinic visits, or those who are positive for the COVID-19 nucleic acid test/positive for the new coronavirus seroantibodies.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    THDB0206 injection

    Drug: THDB0206 injection

  • Active comparator
    Humalog®

    Drug: Humalog®

  • Active comparator
    BC222insulin lispro injection

    Drug: BC222insulin lispro injection

Interventions

  • 0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall

  • 0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall

  • DrugBC222insulin lispro injection

    0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall

06

What researchers measure

Primary outcomes

  1. AUCLisp(0-30 min)

    Area under the insulin lispro plasma concentration-time curve from 0 to 30 minutes

    Time frame: From 0 to 30 minutes

Secondary outcomes

  1. Cmax (Lisp)

    The maximum plasma concentration of insulin lispro observed

    Time frame: From 0 to 8 hours

  2. AUCLisp

    Area under the insulin lispro plasma concentration-time curve

    Time frame: From 0 to 8 hours

  3. tmax(Lisp)

    Time to reach the maximum insulin lispro plasma concentration

    Time frame: From 0 to 8 hours

  4. t1/2

    Terminal half-life

    Time frame: From 0 to 8 hours

  5. CL/F

    Apparent clearance

    Time frame: From 0 to 8 hours

  6. Vz/F

    Apparent volume of distribution

    Time frame: From 0 to 8 hours

  7. AUCGIR

    Area under the glucose infusion rate-time curve

    Time frame: From 0 to 8 hours

  8. GIRtot

    Total glucose infusion during clamping

    Time frame: From 0 to 8 hours

  9. GIRmax

    Maximum glucose infusion rate

    Time frame: From 0 to 8 hours

  10. tGIRmax

    Time to reach the maximum glucose infusion rate

    Time frame: From 0 to 8 hours

  11. Number of participants with abnormal clinical laboratory findings (haematology, biochemistry and urinalysis)

    Time frame: From the first drug administration to the follow-up visit (3 to 10 days after the last drug administration)

  12. Number of participants with abnormal 12-lead ECG parameters (PR, QR, QRS intervals and QTc)

    Time frame: From the first drug administration to the follow-up visit (3 to 10 days after the last drug administration)

  13. Number of participants with abnormal vital signs (body temperature, supine blood pressure and pulse rate)

    Time frame: From the first drug administration to the follow-up visit (3 to 10 days after the last drug administration)

  14. Number of participants with abnormal physical examination (general condition, head and five sense organs, neck, chest, abdomen, spine and limbs, nervous system)

    Time frame: From the first drug administration to the follow-up visit (3 to 10 days after the last drug administration)

  15. Number of participants with hypoglycemia events in each treatment arm

    Time frame: From the first drug administration to the follow-up visit (3 to 10 days after the last drug administration)

  16. Number of participants with injection site reactions (spontaneous pain, tenderness, itching, redness, edema, induration/infiltration)

    Time frame: From the first drug administration to the follow-up visit (3 to 10 days after the last drug administration)

  17. Number of participants with AE and SAE

    Time frame: From the first drug administration to the follow-up visit (3 to 10 days after the last drug administration)

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Sichuan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jun 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Dec 1, 2023
StartActual
Jun 17, 2021
Primary completionActual
Jun 6, 2022
CompletionActual
Jun 6, 2022
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06153329
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
Jun 17, 2021
Primary completion
Jun 6, 2022
Completion
Jun 6, 2022
Last update
Dec 1, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: THDB0206

Start the discussion